Overview

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat and Rituximab for Patients With Relapsed/Refractory Follicular Lymphoma

Status:
Recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to examine the feasibility and efficacy of adding the EZH2 inhibitor, tazemetostat, to rituximab, standard second line or beyond therapy as a means to improve disease response.

Phase:

Phase 2

Details

Lead Sponsor:

Epizyme, Inc.

Collaborator:

Swedish Cancer Institute

Treatments:

Rituximab